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Na+-ATPaseRenal inﬂammation and oxidative stress are constantly present in experimental hypertension. Since the sponta-
neously hypertensive rat (SHR) has reduced levels of hepatocyte growth factor (HGF), which suppresses the ac-
tivation of the proinﬂammatory nuclear transcription factor kappa B (NF-κB), we speculated that HGF deﬁciency
could play a key role in the pathogenesis of hypertension in the SHR. To test this hypothesis we increased HGF in
the SHR by HGF gene delivery. We found that kidneys of 15-week-old SHR had an important reduction in HGF
mRNA and protein expression. Adult SHRs were randomly assigned to receive weekly hydrodynamic injection
(1 mg/kg) of a naked plasmid containing human HGF (hHGF) gene associated with a cytomegalovirus promoter
(pCMV-HGF) or empty vector (pcDNA3.1) during 6 weeks. WKY rats treated with pcDNA3.1 and pCMV-HGF
served as controls. The kidneys in the hypertensive SHR untreated and treated with the empty vector had in-
creased NF-κB activation, elevated mRNA and protein expression of RANTES, MCP-1 and IL-6 and increased ox-
idative stress. Activity of Na+-ATPase was increased while activity of Na+, K+-ATPase was normal. hHGF gene
therapy normalized renal NF-κB activity, proinﬂammatory cytokines, antioxidant status (GSH, SOD and CAT),
Na+-ATPase activity, reduced renal injury and ameliorated hypertension. Our results suggest that reduction in
HGF production plays amajor role in the pathogenesis of hypertension in the SHR and increasing HGF is a poten-
tial therapeutic target in the treatment of hypertension.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Accumulating evidence [1,2] gives strong support to the partici-
pation of renal inﬂammation, and its constant companion, oxidative
stress in the pathogenesis of hypertension by mechanisms that in-
clude, among others, the stimulation of tubular ATPases that play a
central role in sodium reabsorption [3]. Spontaneously hypertensive
rats (SHR) present increased Na+, K+-ATPase activity in early life
before hypertension develops, but the activity of this enzyme,
returns to levels similar to those in normotensive control Wistar
Kyoto rats (WKY) in the adult SHR [4,5]. In contrast, the ouabain in-
sensitive Na+-ATPase [6–9], responsible for the ﬁne tuning of sodi-
um reabsorption, shows augmented activity in the adult SHR [10]
when angiotensin II is increased in the renal cortex and hypertension
is present [11].e Investigaciones Cientíﬁcas
Laboratorio de Señalización
l.: +58 261 3231795.
squez).
l rights reserved.Several strategies aimed to reduce oxidative stress have resulted
in amelioration of hypertension in the SHR. Among these therapies
is the chronic blockade of the proinﬂammatory nuclear transcription
factor kappa B (NF-κB) [12–15] that is activated by oxidative stress
[16,17]. Hepatocyte growth factor (HGF) is a powerful pleiotropic
protein involved in the repair process after injury [18,19], that has
antiapoptotic properties [20,21] and is involved in regulating cell pro-
liferation, differentiation and survival [22]. HGF protects against acute
and chronic injury of multiple organs [23–25] including the kidney
[2,22,26–30]. HGF has potent anti-inﬂammatory effects [25,31] that
include the suppression of NF-κB activation [32], but little is known
about the potential beneﬁts of HGF in hypertensive conditions.
Since Nakano and colleagues [33] showed that HGF content in heart,
aorta and kidney was signiﬁcantly decreased in the SHR, we posited
that deﬁciency in HGF production may represent a central condition
in the pathogenesis of hypertension in the SHR. To test this hypothe-
sis we increased tissue HGF in the SHR by human HGF gene delivery
and examined its effects on NF-κB, inﬂammation markers, oxidative
stress, and in the activity of renal ATPases responsible for the electro-
chemical gradient driving sodium reabsorption.
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2.1. Animals and experimental groups
Male SHRs andWKY rats were obtained from Instituto Venezolano
de Investigaciones Cientiﬁcas (IVIC). The rats were maintained in
temperature controlled institutional facilities with a 12 h light/dark
cycle with free access to standard rat feed and water. The study pro-
tocol was approved by the Bioethics Committee for Animal Research
of IVIC-Zulia. Native HGF mRNA and renal expression were deter-
mined in adult male SHR (n=5) and WKY (n=5) aged 15 weeks.
At 15 weeks of age rats were randomized in six groups: Group 1:
WKY controls rats (WKY, n=6); Group 2: WKY rats treated with
empty vector (WKY-pcDNA3.1, n=6); Group 3: WKY rats receiving
the recombinant human HGF expression plasmid (WKY-pCMV-HGF,
n=6); Group 4: Control SHR (SHR, n=6); Group 5: SHR treated
with empty vector (SHR-pcDNA3.1, n=6), and Group 6: HGF-
treated SHR (SHR-pCMV-HGF, n=6).
Experimental groups received weekly hydrodynamic injections
via the tail vein (1 mg/kg body weight) of human HGF expression
plasmid (groups WKY-pCMV-HGF and SHR-pCMV-HGF) or empty
vector (groupsWKY-pcDNA3.1 and SHR-pcDNA3.1) using a 22 G ven-
ﬂon cannula in a volume equivalent of 5.26% of the body weight, as
described previously [34]. The amount of DNA administered through-
out this study, was deduced from a preliminary study in which vari-
ous amounts of naked DNA were used. The control group was
administered 0.9% saline.
At the time of sacriﬁce (6 weeks of treatment) the rats were eu-
thanized under diazepam–ketamine general anesthesia and after per-
fusion with cold saline solution the kidneys were harvested for
preparation of microsomal and nuclear fraction and western blot
studies and preserved in RNALater for qRT-PCR.
In separate studies, additional groups of animals (n=5, each ex-
perimental group) were transfected with HGF or empty plasmid as
described above to test the efﬁciency of gene delivery. Human
(hHGF) and rat HGF (rHGF) levels were determined on day 3 and 6
after gene delivery in the plasma and in the kidney, respectively.
2.2. Plasmid preparation
The recombinant hHGF expression plasmid that contains the full-
length human HGF cDNA driven under a human cytomegalovirus
(CMV) promoter previously cloned into the BamHI site of plasmid
pcDNA3.1 (Invitrogen) was kindly provided by Dr. Youhua Liu (Uni-
versity of Pittsburgh School of Medicine, Pennsylvania, USA). The
plasmids were transformed into DH-5α and selected on Ampicilline
containing agar plate. The positive clone was then ampliﬁed in
Luria-Bertani (LB) medium. The ﬁnal products of the plasmid in bac-
teria were extracted and puriﬁed using PureYield Plasmid Maxiprep
System (Promega, USA) according to the manufacturer's protocol.
The purity and concentration of the isolated plasmid were conﬁrmed
by agarose gel electrophoresis and spectrophotometry.
2.3. Determination of human and rat plasma HGF
Plasma levels of hHGF and rHGF were determined using commer-
cially available ELISA kits (R&D Systems, Minneapolis, USA). There
was no cross-reactivity between anti-hHGF antibody and rat HGF.
Furthermore, stainings with anti-hHGF antibody in renal sections of
WKY rats and SHR that did not received human HGF were negative.
2.4. RNA extraction and quantitative RT-PCR analysis
Total RNA was isolated from renal cortex using the SV Total RNA
Isolation System (Promega, USA) according to the instructions
speciﬁed by the manufacturer. The ﬁrst strand of cDNA wassynthesized using 1 μg of RNA in 20 μl of reaction buffer with the
use of the M-MLV Reverse Transcriptase System (Promega,
Madison, USA). Quantitative real-time PCR was performed with
the use of the IQ5 Multicolour Real-Time PCR Detection System
(Bio-Rad, USA) which involved the SYBR-based method (Promega,
Madison, USA) in 25 μl reaction volume following the man-
ufacturer's instructions. The primers used in this study (Bioneer
Inc., USA) are as follows: MCP-1 (forward) 5′-AGC CCA GAA ACC
AGC CAA CTC-3′ and (reverse) 5′-GCC GAC TCA TTG GGA TCA TCT
T-3′, RANTES (forward) 5′-ATG AAG ATC TCT GCA GCT GCA TCC-3′,
and (reverse) 5′-CTA GCT CAT CTC CAA ATA GTT G-3′, IL-6 (forward)
5′-GAC TGA TGT TGT TGA CAG CCA GTG C-3′, (reverse) 5′-TAG CCA
CTC CTT CTG TGA CTC TAA CT-3′, HGF (forward) 5′-CCA GCT AGA
AAC AAA GAC TTG AAA GA-3′, and (reverse) 5′-GAA ATG TTT AAG
ATC TGT TTG CGT T-3′ and β-actin (forward) 5′-CAG CTG AGA GGG
AAA TCG TG-3′ and (reverse) 5′-CGT TGC CAA TAG TGA TGA CC-3′.
Quantitative values were obtained from the threshold cycle (Ct)
number that indicates exponential ampliﬁcation of a PCR product
and the relative changes in gene expression were analyzed with
the 2(−Delta Delta C(T)) method [35]. The speciﬁcity of real-time
PCR was conﬁrmed via routine agarose gel electrophoresis and
melting-curve analysis. The housekeeping gene β-actin was used
for normalization.
2.5. Preparation of nuclear fraction
The nuclear fraction was obtained according to the method de-
scribed previously [36]. Brieﬂy, renal tissue wasminced and suspended
in 1 ml of ice-cold buffer A (25 mM Tris–HCl, pH 7.4, 130 mMNaCl and
5 mM KCl) and homogenized. The homogenate was centrifuged at
7000×g for 2 min at 4 °C, the pellet was lysed in 1 ml of ice-cold buffer
B 10 mMHepes, pH 7.9, 10 mMKCl, 0.1 mMEDTA, 0.1 mMEGTA, 1 mM
PMSF, and 1 mM dithiothreitol (DTT) and incubated on ice for 20 min.
Next, 100 μl of Nonidet P-40 was added and vigorously vortexed, and
the extract was centrifuged at 12,000×g for 7 min at 4 °C. The nuclei
then were extracted with 100 μl of ice-cold buffer C 20 mM HEPES, pH
7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF and 1 mM
DTT, incubated on ice for 2 h and centrifuged at 12,000×g for 7 min at
4 °C. The supernatant nuclear fraction was stored at −70 °C. Protein
concentrations were determined using a Bio-Rad Protein Assay kit
(Bio-Rad Laboratories, Hercules, CA, USA) and bovine serum albumin
as a standard.
2.6. Western blot analysis
Western blot studies were done as described previously [37].
Brieﬂy, protein from renal cortex were extracted with lysis buffer
(50 mM Tris–HCl, Glycerol 10%, 1% EDTA, 1 mM PMSF, 1% Triton X-
100, 1 mM EDTA, 5 μg/ml Leupeptine, 1 μg/ml Pepstatin A and 1 μg/
ml Aprotinine) and then centrifuged at 10,000×g at 4 °C for 30 min.
After determination of protein concentration, 40 μg of supernatants
and the nuclear proteins were electrophoresed through 10% SDS-
PAGE in Tris–glycine buffer and blotted onto nitrocellulose mem-
branes in transferring buffer at 80 mA in a transfer apparatus for
2 h. Non-speciﬁc binding to the membrane was blocked for 1 h at
room temperature with 5% non-fat dried milk in Tris-buffered saline
buffer (TBST; 20 mM Tris–HCl, 150 mM NaCl, and 0.1% Tween-20).
The membranes were then incubated overnight at 4 °C with primary
antibodies against IL-6 (Abcam, USA), MCP-1 (Abcam, USA), RANTES
(Abcam, USA), NF-κB p65 (Abcam, USA), β-actin (SIGMA), rat HGF
(Santa Cruz Biotechnology, USA) and Histone H1 (Abcam, USA)
(1:1000 dilution). After extensive washing, the membranes were in-
cubated with horseradish peroxidase-conjugated secondary antibody
for 1 h at room temperature in 1% non-fat dried milk/TBST. Antigen–
antibody complexes were detected with colorimetric detection pro-
cedure, using diaminobenzidine (DAB) as substrate (Biorad, USA)
Fig. 1. Native HGF mRNA (A) renal content (B) and plasma levels (C) in the SHR and
WKY rats. n=6 in each group. Data are mean±SE. ***pb0.001 vs. WKY group.
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Rasband, NIH, Bethesda, MD, USA). Β-actin and Histone H1 were
used as the housekeeping internal control for cytosolic and nuclear
extract respectively.2.7. Preparation of the microsomal fraction
The microsomal fraction was obtained as described by Vieyra et al.
[38]. Brieﬂy, the kidneys were removed and collected in a medium
containing (mM): sucrose 250, Tris–HCl (pH 7.2) 20, dithiothreitol
(DTT) 0.5, EDTA 2 and phenylmethyl-sulfonyl ﬂuoride 1. Then, slices
of the cortex were weighted and homogenized in the same cold solu-
tion using a teﬂon and glass homogenizer. The homogenate was cen-
trifuged at 1000×g for 10 min at 4 °C. The supernatant was
centrifuged at 2000×g for 20 min at 4 °C. The new supernatant was
centrifuged at 48000×g for 1 h at 4 °C. The ﬁnal pellet containing a
microsomal fraction was resuspended in 250 mM sucrose and stored
at −70 °C until use.Fig. 2. Human hepatocyte growth factor (hHGF) protein level after intravenous injec-
tion of naked plasmid. (A) ELISA shows robust expression of hHGF in the plasma
after 72 h of injection of pCMV-HGF plasmid in SHR and WKY rats. (B) Representative
western blots and group data showing exogenous hHGF protein abundance in the kid-
ney after 5 days of injection of pcDNA-HGF in the SHR and WKY rats (n=6 in each
group). Data are mean±SE. ***pb0.001 vs. the WKY and SHR groups that received in-
jection with the empty pcDNA3.1.2.8. ATPase assays
Na+-ATPase and Na+, K+-ATPase assays were determined in the
microsomal fraction according to the method previously described
by Proverbio et al. [39]. The Na+-ATPase activity was assayed as fol-
lows. 180 μl aliquot of the incubation medium containing: 50 mM
Tris–HCl (pH 7.2), 5 mM MgCl2, 2 mM Tris-ATP and 5 mM ouabain,
with and without 100 mM NaCl. In the absence of NaCl, choline chlo-
ride was added to maintain a constant ionic strength. The incubation
medium was pre-incubated at 37 °C for 5 min and the reaction was
initiated by addition of 20 μl of microsomal fraction (0.5 mg protein/
ml). After 10 min incubation, the reaction was stopped by adding
300 μl of a solution containing 2.8% SDS, 0.48% molybdic acid, 2.8%
ascorbic acid and 0.48 N hydrochloride acid. The tubes were placed
on ice for 10 min, and then mixed with 500 μl of a solution containing
2% sodium arsenite, 2% sodium citrate and 2% acetic acid. The tubes
were rewarmed at 37 °C for 10 min and the developed color was
measured in a spectrophotometer at 705 nm. All determinations
were run in triplicate.The Na+-ATPase activity was calculated as the difference be-
tween the amount of inorganic phosphate liberated in the presence
of Mg+2+Na++5 mM ouabain minus that liberated in the pres-
ence of Mg+2+5 mMouabain. The Na+, K+-ATPase activity was de-
termined by using a similar protocol but with an incubation medium
containing 50 mM Tris–HCl (pH 7.2), 5 mM MgCl2, 100 mM NaCl,
20 mM KCl and 2 mM Tris-ATP, with and without ouabain. The
Na+, K+-ATPase activity was calculated as the difference between
the amount of inorganic phosphate liberated in the presence of
Mg+2+Na++K+ minus that liberated in the same medium in the
presence of 5 mM ouabain. The activity was expressed as nanomoles
of Pi liberated per mg of protein per min, after substration of a blank
run in parallel without the membrane suspension, which was added
after the reaction was stopped.
2.9. Malondialdehyde (MDA) determination
Renal tissue was homogenized in lysis buffer (100 mM KCl, 3 mM
EDTA and 2% butylated hydroxytoluene). Homogenate was cen-
trifuged at 600×g for 15 min and the collected supernatants were an-
alyzed by the method of Ohkawa et al. [40] as described in previous
communications [37]. Results are expressed as nanomoles MDA per
milligram protein (Bio-Rad Protein Assay kit, Laboratories, Hercules,
CA, USA).
2.10. Renal cortical glutathione (GSH) assay
GSH was determined as non-protein and total sulfhydryl content in
rat kidney using the method by Sedlak and Lindsay [41]. Renal tissue
homogenates were centrifuged at 600 g for 10 min. and 1 ml of super-
natant were added to 1.5 ml methaphosphoric acid and centrifuged at
3000 g for 10 min. Reduced GSH was measured by adding 500 μl of su-
pernatant to 2 ml of 0.2 M phosphate buffer and 0.25 ml 0.04% 5,5′
dithio-bis-2-nitrobenzoic acid (DTNB). Absorbance was read at
410 nm. GSH (SIGMA) was used as the external. GSH content was
expressed as nanomoles of GSH per milligram homogenate protein.
2.11. Superoxide dismutase (SOD) and catalase (CAT) activity
The SOD activitywasmeasured spectrophotometrically as previous-
ly reported [42]. The assay is performed in 3 ml of 50 mM potassium
phosphate buffer pH containing 0.1 mM ethylenediaminetetraacetic
acid (EDTA), 0.01 mM cytochrome C, 0.05 mM xanthine, and sufﬁcient
xanthine oxidase to produce a cytochrome c reduction rate at 550 nm
Fig. 3. Rat hepatocyte growth factor (rHGF) protein level after intravenous injection of naked plasmid. (A) ELISA shows expression of rHGF in the plasma after 6 weeks of weekly
injection of pCMV-HGF plasmid in SHR and WKY rats. (B) Representative western blots and group data showing rHGF protein abundance in the kidney at the end of study in the
SHR and WKY rats (n=6 in each group). Data are mean±SE. ***pb0.001 vs. the SHR-pcDNA3.1 group that received injection with the empty pcDNA3.1.
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performed in presence of 1 mM potassium cyanide (KCN), selective in-
hibitor of copper–zinc (Cu/Zn) SOD, to differentiate Cu/Zn SOD and
MnSOD isoenzymes. Catalase activity was assayed spectrophotometri-
cally by the conversion of 10 mMH2O2 in 50 mMpotassiumphosphate,
0.1 mM EDTA. Calculation was based on ε=0.0425 mM−1 cm−1
(where ε is the extinction coefﬁcient) for H2O2 at 240 nm and the
change in absorbance during the ﬁrst 60 s of the reaction [43].
2.12. Blood pressure measurements
Systolic BP was measured weekly in conscious restrained rats
using tail–cuff plethysmography (IITC, Life Scientiﬁc Instruments,
Woodland Hills, CA, USA) as described in previous communications
[13,15,44,45]. Preconditioned animal rats were allowed to rest in
the restrainer for 10–15 min, the cuff was inﬂated and released sever-
al times and blood pressure used was the average of 3 determinations
obtained after stabilization. Blood pressure determinations were
obtained by the same trained technician that was blinded to the ex-
perimental group of the animal.
2.13. Blood and urine analysis
Blood samples (1 ml) were collected into heparinized tubes from the
caudal vein of each rat before the beginning of the experiment (basal
values) and then once weekly. Plasma was separated from blood byTable 1
Mean ﬁnal body weight, ending systolic blood pressure and mean value of selected urine a
Groups WKY
(n=6)
WKY-pcDNA3.1
(n=6)
WKY-pCMV-HG
Body weight
Pre 280±1 290±8 287±20
Post 353±40 373±20 345±32
SBP (mmHg)
Pre 120±2.7 121.6±3.05 117±2.58
Post 121±6.8 122.4±7.1 116±4.5
Pcr (mg/dl)
Pre 0.43±0.2 0.35±0.1 0.36±0.2
Post 0.41±0. 0.38±0.09 0.33±0.06
Uprot V
(mg/24 h)Pre 2.2±1.8 2.8±2.1 1.9±3.1
Post 3.0±1.3 2.4±1.6 2.8±1.7
⁎⁎⁎ pb0.001 vs. WKY.
### pb0.001 vs. SHR-pcDNA3.1.centrifugation at 16,000×g for 5 min. Blood urea nitrogen (BUN) and cre-
atinine were determined using an Express Plus automated analyser
(Chiron Diagnostics, Emeryville, CA, USA). Urine samples were collected
before starting the experiment and then once weekly. Animals were
housed in individual metabolic cages for 24 h. Urinary volume was mea-
sured gravimetrically in preweighed vials. Urine was used to determine
protein concentration by the Bio-Rad kit (Bio-Rad, Hercules, CA).
2.14. Histological evaluation of renal injury and renal ﬁbrosis
For light microscopy, tissue sections were ﬁxed in 4% formaldehyde,
embedded in parafﬁn and stainedwith HE, PAS andMasson's trichrome
stainings. Glomerular injury was evaluated as described by Kusunoki et
al. [46], using glomerular injury scores graded from 0 to 4+ depending
on the extension (%) of the damage in the glomerular tuft. At least 20
glomeruli were examined per kidney section and classiﬁed as
0=b10%, 1+=10% to 25%, 2+=26% to 50%; 3+=51% to 75% and
4+=>75%. The score assigned to the kidney corresponded to the
mean score of the glomerular examined. Tubulointerstitial injury was
graded by the extension of the damaged area (dilatation, atrophy, in-
ﬂammatory inﬁltration, ﬁbrosis) as 0 (b10%), 1+ (10% to 25%), 2+,
(26% to 50%), 3+ (51% to 75%) and 4+, (>75%) as described previously
[14]. Renal ﬁbrosis was evaluated in the Mason's trichrome staining of
the renal sections using computer assisted image analysis. Pathological
analyses were done by a single observer (MC) blinded to the group of
the rat under scrutiny.nd plasma parameters for each study group at the end of the experiment.
F(n=6) SHR
(n=6)
SHR-pcDNA3.1
(n=6)
SHR-pCMVHGF
(n=6)
278±11 269±23 282±10
371±18 361±35 368±15
156.2±7.08 152.2±7.67 149.6±1.67
174±4.3*** 177±3.9 138±3.2###
0.42±0.12 0.39±0.09 0.43±0.11
0.42±0.09 0.40±0.14 0.34±0.12
8.9±2.1 11.9±3.1 9.2±7.2
25.3±2.1*** 28±1.3 4.8±1.8###
Fig. 4. Representative western blots and group data showing p65 NF-κB content in the
nuclear fraction of the kidneys of the experimental and control groups. Renal nuclear
content of p65 NF-κB is increased in the groups of untreated SHR and the SHR treated
with empty plasmid (SHR-pcDNA3.1 group). Administration of HGF gene therapy
(SHR-pCMV-HGF group) inhibits NF-κB nuclear translocation and p65 levels are
maintained at levels found in the WKY controls rats. Data shown are mean±SE.
n=6 in each group. ***pb0.01 vs. WKY, ###pb0.01 vs. SHR-pcDNA3.1.
Fig. 5. Effect of HGF gene therapy on the mRNA expression (A) and protein content (B)
of IL-6 in the experimental groups (n=6 in each group). (B) Data are mean±SE.
***pb0.01 vs. WKY, ##·pb0.01 vs. SHR-pcDNA3.1.
Fig. 6. Effect of HGF gene therapy on the mRNA (A) and protein content (B) MCP-1 in
the experimental group (n=6 in each group). Data are mean±SE. ***pb0.01 vs. WKY,
###pb0.01 vs. SHR-pcDNA3.1.
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All data are presented as mean±SE. Statistical differences were
examined by analysis of variance (ANOVA) and Tukey post-tests
using a commercially available statistical package (GraphPad Soft-
ware Version 5.0, La Jolla, CA). Paired (repeated measurements)
tests were used to evaluate blood pressure changes within groups
over time and multiple-group ANOVA for testing differences between
groups. Differences with two-tailed p valuesb0.05 were considered
statistically signiﬁcant.
3. Results
3.1. Native HGF mRNA and renal content in the SHR and WKY
As shown in Fig. 1, The 15 weeks old WKY rats had 4 times higher
renal rHGF mRNA (Fig. 1A) and more than 3 times higher rHGF renal
content (Fig. 1B) than the age and sex paired SHR. In contrast, plasma
levels of native HGF (rHGF) in SHR are more than two times higher
than the levels in the WKY rat (Fig. 1C).
3.2. Plasma levels and renal expression of hHGF after systemic gene
delivery of hHGF
To test the efﬁciency of gene delivery, human HGF (hHGF) levels
were determined on day 3 and 6 after gene delivery in the plasma
and in the kidney, respectively. Systemic administration of pCMV-
HGF produced a substantial level of exogenous hHGF protein in the
Fig. 7. Effect of HGF gene therapy on the mRNA (A) and protein content of RANTES in
the experimental groups (n=6 each group). Data are mean±SE. ***pb0.01 vs. WKY,
##3pb0.01 vs. SHR-pcDNA3.1.
Fig. 8. Effect of HGF gene delivery on glutathione (A) and malondialdehyde (B) in renal
cortical homogenates in the experimental and control groups (n=6 in each group).
Data are mean±SE. **pb0.01 vs. WKY, ##pb0.01 vs. SHR-pcDNA3.1.
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ic ELISA revealed 1.76±0.079 ng/ml of hHGF at day 3 after hydrody-
namic injection of pCMV-HGF (Fig. 2A). The expression of hHGF
transgene in the kidney was sustained for at least 6 days (Fig. 2B).
As expected, hHGF was not detectable in the plasma and kidneys
when rats were injected with empty pcDNA3.1 plasmid in an
identical manner.3.3. Plasma rHGF concentration and expression in renal tissue after hHGF
gene delivery
To evaluate whether exogenous hHGF affects the endogenous ex-
pression of rHGF, a rat speciﬁc enzyme-linked immunosorbent assay
was performed. As shown in Fig. 3A, plasma rHGF levels were signif-
icantly decreased by systemic administration of pCMV-HGF, whereas
renal rHGF expression was signiﬁcantly increased by treatment with
pCMV-HGF (Fig. 3B).3.4. Effects of HGF gene delivery on body weight and renal function
Table 1 shows the ﬁndings at baseline (Pre) and the end of the ex-
periments. No signiﬁcant differences in body weights or plasma cre-
atinine levels were observed during the experiment. The mean
urinary protein excretion at the end of the study period was moder-
ately, but signiﬁcantly increased in the SHR untreated and treated
with the empty vector (SHR and SHR-pcDNA3.1 groups) and the
treatment with hHGF prevented proteinuria (Table 1).3.5. HGF gene delivery blocks renal NF-κB activation and
proinﬂammatory cytokines
The effects of HGF gene delivery on the activation of the NF-κB sig-
nal pathway and the expression of proinﬂammatory cytokines is
shown in Fig. 4 through 7. Fig. 4 shows that the DNA binding p65 sub-
unit of NF-κB was markedly increased in the renal cortex of SHR rats
(pb0.01), and hHGF gene delivery prevented NF-κB activation, as de-
termined by reduction of the p65 subunit to levels comparable to
those in the control WKY rats.
Fig. 5 shows that IL-6 mRNA and renal protein expression were
signiﬁcantly higher in the SHR rats than in the age-matched WKY.
The HGF gene delivery was able to correct the increase in the IL-6
mRNA levels (Fig. 5A) and protein content (Fig. 5B), the administra-
tion of pCMV-HGF plasmid to WKY rats did not modify the IL-6
mRNA and protein levels. Similar ﬁndings were observed with the
mRNA and protein expression of the chemotactic factor MCP-1
(Fig. 6A and B) and with RANTES (Fig. 7A and B) that were increased
in the SHR and reversed to levels similar to those in control WKY rats
by HGF gene delivery.
As expected, intravenous injection of empty pcDNA3.1 plasmid
vector produced no changes in mRNA and protein levels of IL-6,
MCP-1 and RANTES in WKY and SHR rats (Figs. 5–7).
3.6. Effect of HGF gene delivery on oxidative stress markers in the kidney
of WKY and SHR
The levels of reduced glutathione (GSH) were similar in all WKY
rat groups (Fig. 8A). In contrast, GSH levels were markedly decreased
in both the untreated SHR and the SHR treated with the empty vector
(SHR-pcDNA3.1 group). hHGF gene delivery signiﬁcantly increased
renal levels of GSH (pb0.01) in SHR. Fig. 8B shows themalondialdehyde
AWK
Y
WK
Y-p
cD
NA
3.1
WK
Y-p
CM
V-H
GF SH
R
SH
R-p
cD
NA
3.1
SH
R-p
CM
V-H
GF
0
10
20
30
40
50
***
###
***
Cu
/Z
n 
SO
D 
ac
tiv
ity
(U
/m
g 
pr
ot
ei
n
)
B
Fig. 9. Effect of HGF gene therapy on Cu/Zn SOD (A) and catalase (B) activity in renal
cortex of experimental and control groups (n=6 each group). Data are mean±SE.
**pb0.01 vs. WKY, ##pb0.01 vs. SHR-pcDNA3.1.
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untreated SHR and SHR treatedwith empty vector had highMDA levels.
HGF gene therapy prevented the increase in MDA levels in SHR (Fig. 8B,
pb0.001).
3.7. Effect of HGF gene therapy on the activities of antioxidants enzymes
in the kidney of WKY and SHR
Superoxide dismutase (SOD) activity in the kidney of control and
plasmid-treated experimental groups was signiﬁcantly (pb0.01) re-
duced in the SHR and HGF gene delivery resulted in an increment of
SOD activity to normal levels (Fig. 9A). In contrast, renal catalase
(CAT) activity was increased in SHR and was reduced to normal levels
by HGF gene therapy. No changes were observed in WKY rats with
the administration of pCMV-HGF (Fig. 9A and B).
3.8. Effects of HGF gene therapy on the activity of renal ATPases
SHR and WKY rats of 15 weeks of age have similar levels of Na+,
K+-ATPase that were not modiﬁed by gene therapy (Fig. 10A). In con-
trast, ouabain-insensitive furosemide-sensitive Na+-ATPase is signif-
icantly increased (pb0.001) in hypertensive adult SHR and was
reduced to normal levels by the HGF gene delivery (Fig. B). Adminis-
tration of empty vector pcDNA3.1 produced no changes in the activity
of ATPases (Fig. 10A and B).
3.9. HGF gene therapy prevents spontaneously hypertension
Fig. 11 shows the blood pressure changes during the experiment.
As expected, the baseline systolic blood pressure (SBP) of 15-week-old SHR was signiﬁcantly higher than in aged-matched WKY. The
blood pressure of the untreated SHR and the SHR treated with the
empty vector (SHR-pcDNA3.1 group) continued to increase and
reached mean values 174±4.3 mmHg and 177±3.9 mmHg, respec-
tively after 6 weeks. In contrast, the blood pressure of the SHR that re-
ceived HGF gene delivery (SHR-pCMV-HGF group) did not increase
and remained at steady levels during the 6 weeks of HGF delivery
(pb0.01 vs. the SHR untreated and treated with the empty vector
from the ﬁrst week through the last week of the experiment
(Fig. 10)). The administration of HGF gene to the WKY rats did not
Fig. 12. Effect of hHGF gene delivery on kidney injury in SHR. The histological examination (staining) was carried out when the animals were euthanized at 6 weeks after gene
delivery (21 weeks old). Upper panels show glomerular injury, renal ﬁbrosis and tubulointerstitial injury scores (see text). Microphotographs demonstrate representative
trichrome staining of renal sections from WKY rats (A), SHR (B) and SHR treated with rHGF (SHR-pCMV-HGF) (C). Lower microphotographs show a higher magniﬁcation of an
area in the corresponding upper microphotograph to illustrate the reduction in renal ﬁbrosis (stained blue) in the SHR induced by HGF gene delivery. Data are mean±SE,
***pb0.001 vs. WKY, ##pb0.01 vs. SHR-pcDNA3.1.
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gene delivery, 116±4.5 mmHg, (Fig. 10)).
3.10. HGF gene delivery protects from renal injury in SHR
Glomerular and tubulointerstitial injury was present in the SHR
and improved by hHGF gene delivery. Histological ﬁndings are
shown in Fig. 12. Representative microphotographs are shown in
the lower panels and quantitation of injury in the upper panels. The
changes observed in tubulointerstitial areas were areas with tubular
dilatation and cellular atrophy and a moderate increment in intersti-
tial ﬁbrosis. Glomerular changes included mesangial expansion and
focal areas of hypercellularity.
4. Discussion
Spontaneously hypertensive rats have reduced tissue expression
and increased plasma levels of HGF [33]. The reason for this contrast
is incompletely understood but it has been postulated that reduced
tissue HGF promotes remodeling in target organs of hypertension
and increased circulating levels of HGF, which are correlated with
the severity of hypertension, are elevated as a counter-system against
cardiovascular dysfunction. While the present investigation was not
directed to examine the mechanisms of increased circulating levels
of HGF in the SHR, we observed that gene delivery of exogenous
(human) HGF resulting in increased renal expression of HGF, amelio-
rated hypertension and was accompanied by a reduction in plasmalevels of native (rat) HGF. Therefore our data is consistent with a pre-
viously demonstrated direct relationship between blood pressure and
plasma levels HGF [33].
Using a hydrodynamics-based systemic in vivo gene transfer strat-
egy we were able to induce the overabundance of exogenous HGF
protein (hHGF) in the kidney of the SHR that is known to have a re-
duced HGF content [33]. We reasoned that the reduction in HGF
could have pathogenetic relevance because one of the effects of HGF
is to suppress activation of NF-κB [32]. In fact, studies by our group
[15] and others [12] have shown that blockade of NF-κB activation
corrects hypertension in the SHR. The present studies demonstrate
that HGF gene delivery resulted in suppression of the NF-κB activa-
tion and in the reduction of proinﬂammatory cytokines and markers
of oxidative stress to normal levels. In addition, our results demon-
strated that hHGF gene therapy reduced proteinuria and suppressed
kidney injury and ﬁbrosis in the SHR. The anti-inﬂammatory effect of
HGF has been previously proved in other chronic renal conditions
such as the remnant kidney model [26,47], renal allograft rejection
[27] and puromycin aminonucleoside nephrosis [48] but, to our knowl-
edge, this is the ﬁrst demonstration that HGF gene therapy is beneﬁcial
in genetic hypertension and adds pathophysiologic relevance to obser-
vationsmade byNakano et al. [33], conﬁrmed here, that the SHR has re-
duced levels of HGF prior to the development of hypertension.
The mechanisms by which HGF suppresses NF-κB activation are
incompletely deﬁned. Studies by Gong et al. [32] suggest that HGF
prevents GSK-3β phosphorylation, thus preventing activation of NF-
κB and a recent work by Benkhoucha et al. [49] indicates that HGF
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ed to identify the relative relevance of these mechanisms in relation
to the reduced HGF production in the SHR. The ﬁnding that native
HGF mRNA is lower in SHR than in the control WKY rats, taken to-
gether with the protection offered by HGF gene therapy, suggests
that a genetic deﬁciency of HGF may play a role in the pathogenesis
of hypertension in the SHR.
Accumulating evidence in a variety of experimental models has
provided support for the participation of renal inﬂammation in the
pathogenesis of hypertension [1] and the present studies conﬁrm
the investigations that have shown the relevance of renal inﬂamma-
tion in the pathogenesis of hypertension in the SHR [12,14,50].
Renal inﬂammation results in a rightward shift of the pressure natri-
uresis relationship [51] and recent investigations have unraveled
roles of IL-6 [52], TGF-β [53] and MCP-1 [54] in the renal pathophys-
iology of sodium transport. In the present studies we show an in-
crease in IL-6, MCP-1 and RANTES mRNA and protein expression in
the SHR, all of them corrected by HGF gene therapy.
The pathophysiology of sodium retention in the SHR is incom-
pletely deﬁned. The Na+, K+-ATPase, responsible for the bulk of sodi-
um reabsorption is increased in the young prehypertensive SHR but is
not changed in animals more than 12 weeks of age [4,5,10]. In con-
trast, the recently cloned [9] ouabain insensitive Na+-ATPase is in-
creased in the adult SHR and since it is assumed to be involved in
the ﬁne tuning of Na+ reabsorption and its increment is associated
with the increment in angiotensin II activity, it may have a relevant
role in the sustained tendency to sodium retention of the SHR [10].
We therefore examined both ATPases and conﬁrmed that the
15 weeks old hypertensive SHR had normal Na+, K+-ATPase activity
while the activity of the Na+-ATPase was signiﬁcantly elevated
(Fig. 10). The activity of the Na+-ATPase was reduced to levels similar
to those inWKY control rats by HGF gene delivery, in association with
a reduction in inﬂammatory markers and oxidative stress, suggesting
that oxidative stress may play a role in the sustained activation of the
Na+-ATPase. Since oxidative stress is known to induce activation of
the Na+, K+-ATPase associated with AT1 receptor upregulation [3],
it is unclear why the adult hypertensive SHR that presents increased
oxidative stress, only has increased activity of the ouabain sensitive
Na+-ATPase. At any rate, the present studies raise the possibility
that the renal Na+-ATPase may play a role in the impairment of pres-
sure natriuresis that deﬁnes salt-sensitive hypertension since anti-
inﬂammatory treatments prevent or ameliorate the blood pressure
increment induced by a high salt diet in several experimental models
[1,30,55].
Oxidative stress is a constant companion of inﬂammation [54];
therefore it is not unexpected that suppression of inﬂammation,
resulting fromHGF gene therapywould be associatedwith a normaliza-
tion of the redox balance. In addition to indirect effects due to suppres-
sion of inﬂammation, HGF can protect from oxidative damage by a
mechanismdriven by PI3K/AKT signaling [56,57]. In the present studies,
HGF gene therapywas associatedwith a reduction in the renalMDAand
GSH content that were found increased in the SHR. Cu/Zn SOD activity
was signiﬁcantly decreased in SHR and restored to normal values by
HGF treatment. Since HGF does not directly stimulate antioxidant en-
zymes and the increment in SOD is likely the result of decreased con-
sumption resulting from a reduction in reactive oxygen species
generation as inﬂammation is suppressed. Unexpectedly, CAT activity
in the kidney of SHRwas higher than the values in age-matched control
WKY rats. CAT catalyzes the reduction of H2O2 concentration to water
and oxygen. The increment in CAT activity may represent a compensa-
tory response aimed at disposing of the H2O2 generated at a high rate in
the SHR [58] and thereby protecting the kidney from the toxic effects of
hydroxyl radical accumulation. Of note, hHGF gene therapy did not
modify the NF-κB activity or markers of inﬂammation or oxidative
stress in the WKY rats. These ﬁndings indicate that HGF-related sup-
pression of NF-κB activation and downstream proinﬂammatorycytokines is evident only when proinﬂammatory stimulation of
these mediators is present.
In summary, the present study offers evidence of reduced produc-
tion of HGF in the SHR that, if corrected with HGF gene therapy, results
in reduction of renal inﬂammation and oxidative stress, normalization
of the upregulated Na+-ATPase and suppression of the progressive se-
verity of hypertension that characterizes the natural history of this rat
strain. These ﬁndings offer new insights on the pathogenesis of high
blood pressure in the SHR and identify HGF increment as a novel target
in the therapy of hypertension.
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